

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

## Arcimoto, Inc. (NASDAQ: FUV)

October 7, 2022

### Sell: \$50M SPA Expected to Further Pressure Shares

Arcimoto announced a \$50 million share purchase agreement that we believe will further pressure the shares. We maintain our Sell recommendation and \$0.45 price target.

This week, Arcimoto announced a \$50 million share purchase agreement that we believe will further pressure the shares. The agreement, with Tumim Stone Capital, would potentially raise \$50 million for Arcimoto. Tumim Stone will pay a 5% discount to the 3-day VWAP and is limited to owning 4.99% of the shares outstanding, or 9.99% with a 61-day prior written notice.

At the current price, almost 50 million shares would be issued to raise the full \$50 million, more than the current number of shares outstanding currently. In order to stay under the 4.99%/9.99% cap, a significant number of shares would need to be sold in the open market before further shares could be issued by the company.

This agreement requires shareholder approval, and since the company is required to call a special meeting of shareholders no later than October 31 to approve the \$20 million convertible note issued earlier, a vote on this transaction may also occur then.


At the end of June, Arcimoto had \$5 million in cash. We estimate the company raised about \$10 million via its ATM since the end of Q2 and raised another \$9.4 million with a convertible note. Assuming a cash burn of \$10 to \$12 million per quarter, this leaves the company with \$12 to \$14 million in cash, or enough to get through the early part of Q1 2023.

Our Sell recommendation is based on the significant mismatch between the company's cash needs and cash resources. We expect the company will have to confront painful choices over the coming months as its cash needs are exigent and options are dwindling. We believe the company will be forced to cut costs and scale back its plans for manufacturing capacity. This will result in a reduction in consensus estimates. Our \$0.45 price target is an enterprise value of \$20 million, which is the exercise floor price of the recently issued warrant until stockholder approval is received for the second tranche of notes. Risks to achieving our stock price include financing at terms better than we expect, government subsidies or a takeover.

**James McIlree, CFA**  
 561-237-2709

jmcilree@dawsonjames.com

Current Price	\$1.07		
Price Target	\$0.45		
Estimates	F2021A	F2022E	F2023E
Revenues (\$000s)	\$ 4,386	\$ 4,550 E	\$ 5,700
1Q March	\$ 1,394	650 A	\$ 1,425
2Q June	\$ 717	\$ 1,499 A	\$ 1,425
3Q September	\$ 1,498	\$ 1,200 E	\$ 1,425
4Q December	\$ 777	\$ 1,200 E	\$ 1,425
	F2021A	F2022E	F2023E
EBITDA (\$000s)	\$ (38,842)	\$ (44,957)E	\$ (35,345)
1Q March	\$ (6,553)	\$ (10,811)A	\$ (8,814)
2Q June	\$ (8,086)	\$ (12,345)A	\$ (8,851)
3Q September	\$ (9,645)	\$ (11,821)E	\$ (8,821)
4Q December	\$ (14,557)	\$ (9,981)E	\$ (8,859)
EV/Sales	NM	10.3 x	8.2 x
EV/EBITDA	NM	(1.0) x	(1.3) x
<b>Stock Data</b>			
52-Week Range	\$1.06	-	\$13.26
Shares Outstanding (mil.)	44.9		
Market Capitalization (mil.)	\$48		
Enterprise Value (mil.)	\$47		
Debt to Capital	22%		
Cash & Equivalents (mil.)	\$23.4		
Cash/Sh.	\$0.52		
Average Three Months Trading Volume (K)	1,267		
Insider Ownership	17.5%		
Institutional Ownership	18.1%		
Short interest (mil.)	22.1%		
Dividend / Yield	\$0.00/0.0%		



:

## Outlook

We project revenue in 2022 of \$4.6 million and \$5.7 million in 2023. These projections are significantly lower than consensus and reflect our belief the company will need to implement cash conservation measures that will impact its ability to grow production and expand sales and marketing. Even so, we project EBITDA losses of \$47 million this year and \$39 million in 2023. And this is before the \$35 million to \$40 million the company has identified it will need for capital expenditures in 2022 and a like amount in both 2023 and 2024. Unless the company is able to find capital to fund these plans, we expect consensus estimates will have to decline sharply.

We estimate current cash balances are not adequate to fund the company's plans. We have assumed capital raises in 2022 and 2023 to fund the company's operations and growth. We believe the need to raise capital will pressure the shares until that uncertainty is mitigated.

## Valuation

Ayro and ElectraMeccanica, like Arcimoto, are producing electric vehicles, Ayro for the delivery market and ElectraMeccanica for the consumer market. Both trade close to enterprise value.

		Price	FTM EPS	P/E	TEV (M)	FTM Sales (M)	EV/ Sales	FTM EBITDA	EV/ EBITDA
AYRO	AYRO, Inc.	\$ 0.59	\$ (0.45)	(1.3)	\$ (35.6)	\$ 2.8	(12.9)	\$ (8.9)	4.0
SOLO	ElectraMeccanica Vehicles Corp.	1.21	(0.52)	(2.3)	(9.2)	29.7	(0.3)	(57.1)	0.2
GPV-CA	GreenPower Motor Company Inc.	2.46	(0.30)	(8.2)	60.0	50.4	1.2	(3.4)	(17.8)
WKHS	Workhorse Group Inc.	2.65	(0.52)	(5.1)	312.3	62.1	5.0	(82.1)	(3.8)
	Average						(1.7)		
FUV	Arcimoto, Inc.	\$ 1.07	\$ (1.03)	(1.0)	\$ 46.7	\$ 5.4	8.6	\$ (37.3)	(1.3)

Source: FactSet and Dawson James Securities estimates

Our price target of \$0.45 is an enterprise value above both AYRO and ElectraMeccanica. It is also the exercise floor price of the warrant until stockholder approval is received for the second tranche of notes.

The risk of the share price falling below our price target includes the company avoiding actions to cut costs, which would increase cash burn, raising funds at increasingly onerous terms resulting in a spiral of ever-increasing share issuances at lower prices or inability to raise capital altogether. Risks that the share price moves opposite the trajectory predicted in our price target include a takeover, a rally in equity markets that includes Arcimoto, funding from federal, state or local governments, or changes in government policies that drive demand for Arcimoto's products.

**Exhibit 1. Income Statement**

(\$ in 000's) (except per share data)	FY2019	FY2020	FY2021	Q1 22A	Q2 22A	Q3 22E	Q4 22E	FY2022E	FY2023E
<b>Revenue</b>	<b>\$ 988</b>	<b>\$ 2,176</b>	<b>\$ 4,386</b>	<b>\$ 650</b>	<b>\$ 1,499</b>	<b>\$ 1,200</b>	<b>\$ 1,200</b>	<b>\$ 4,550</b>	<b>\$ 5,700</b>
COGS	2,911	8,251	17,149	4,047	6,104	5,865	5,390	21,406	22,279
Gross Profit	(1,924)	(6,075)	(12,763)	(3,397)	(4,605)	(4,665)	(4,190)	(16,857)	(16,579)
R&D	6,032	3,011	12,106	3,907	3,716	3,754	3,316	14,693	10,151
Sales & Marketing	1,005	2,239	7,000	2,927	3,070	3,101	2,657	11,755	10,788
G&A	5,494	6,091	12,948	2,699	3,786	3,200	2,757	12,442	10,395
Impairment			6,824					0	0
Opex	12,532	11,341	38,879	9,532	10,572	10,055	8,730	38,889	31,334
Operating Income	(14,455)	(17,416)	(51,642)	(12,929)	(15,177)	(14,719)	(12,920)	(55,746)	(47,914)
Interest Income	0	0	0	0	0	0	0	0	0
Interest Expense	(892)	(721)	(216)	(50)	(124)	(124)	(265)	(563)	(872)
Other	5	17	1,360	25	(2,100)	(2,100)	(2,100)	(6,274)	(8,398)
Pretax Income	(15,342)	(18,120)	(50,498)	(12,954)	(17,401)	(16,943)	(15,284)	(62,582)	(57,184)
Taxes	0	0	(2,934)	0	3	0	0	3	0
<b>Net Income</b>	<b>\$ (15,342)</b>	<b>\$ (18,120)</b>	<b>\$ (47,564)</b>	<b>\$ (12,954)</b>	<b>\$ (17,404)</b>	<b>\$ (16,943)</b>	<b>\$ (15,284)</b>	<b>\$ (62,586)</b>	<b>\$ (57,184)</b>
Basic Shares	18,130	28,575	36,704	37,967	39,573	43,321	57,260	44,530	80,288
Basic EPS	\$ (0.85)	\$ (0.63)	\$ (1.30)	\$ (0.34)	\$ (0.44)	\$ (0.39)	\$ (0.27)	\$ (1.41)	\$ (0.71)
Operating Income	(14,455)	(17,416)	(51,642)	(12,929)	(15,177)	(14,719)	(12,920)	(55,746)	(47,914)
Depreciation	710	930	2,348	707	1,020	1,087	1,127	3,942	5,321
Stock Comp	635	1,917	3,628	1,411	1,812	1,812	1,812	6,847	7,248
Other			6,824						
<b>EBITDA</b>	<b>\$ (13,109)</b>	<b>\$ (14,569)</b>	<b>\$ (38,842)</b>	<b>\$ (10,811)</b>	<b>\$ (12,345)</b>	<b>\$ (11,821)</b>	<b>\$ (9,981)</b>	<b>\$ (44,957)</b>	<b>\$ (35,345)</b>

Source: Arcimoto, Inc. and Dawson James Securities estimates

**Exhibit 2. Balance Sheet and Cash Flow Statement**


(\$ in 000's)	FY2019	FY2020	FY2021	FY2022E	FY2023E
Cash	5,832	39,451	16,971	18,886	27,451
A/R	244	17	128	274	456
Inventory	3,734	5,104	7,856	9,582	6,855
Prepaid Inventory	1,195	1,030	2,638	2,749	2,749
Other	665	901	2,440	3,661	4,347
<b>Current Assets</b>	<b>11,671</b>	<b>46,503</b>	<b>30,033</b>	<b>35,153</b>	<b>41,858</b>
PP&E	4,733	6,645	24,339	31,120	37,641
Intangible Assets	0	0	9,886	9,044	8,202
Operating lease right of use	0	0	0	1,636	1,636
Other	42	102	141	117	117
<b>Total Assets</b>	<b>\$ 16,446</b>	<b>\$ 53,250</b>	<b>\$ 64,399</b>	<b>\$ 77,070</b>	<b>\$ 89,455</b>
A/P	340	205	2,016	2,207	2,621
Accrued Liabilities	816	431	2,352	2,170	2,577
Customer Deposits	794	606	817	1,079	1,079
NP (net of discount)	3,032	479	2,533	1,706	1,706
Leases (finance and capital)	434	247	352	1,064	1,064
Convertible NP-related Parties	1,151	0	0	0	0
Convertible NP (net of discount)	838	0	0	5,000	3,750
Other	121	289	544	520	520
Note Payable-Other	0	658	0	0	0
<b>Current Liabilities</b>	<b>7,525</b>	<b>2,914</b>	<b>8,614</b>	<b>13,746</b>	<b>13,317</b>
Finance Lease	1,180	535	713	547	547
Equipment notes/LTD	0	2,001	1,185	1,042	1,042
Convertible note	0	0	0	10,477	6,727
Warranty Reserve	45	67	330	353	353
Operating lease	0	0	0	1,043	1,043
Deferred Revenue	86	50	9	5	5
Equity	7,610	47,684	53,548	49,858	66,422
<b>Total Liabilities &amp; Equity</b>	<b>\$ 16,446</b>	<b>\$ 53,250</b>	<b>\$ 64,399</b>	<b>\$ 77,070</b>	<b>\$ 89,455</b>
	FY2019	FY2020	FY2021	FY2022E	FY2023E
Net Income	(15,342)	(18,120)	(47,564)	(62,586)	(57,184)
Depreciation	710	930	2,348	3,942	5,321
Stock Comp	635	1,917	3,628	6,847	7,248
Other	1,186	310	2,807	2,802	0
Working Capital	(1,481)	(1,330)	(511)	(1,770)	2,679
<b>Operating CF</b>	<b>\$ (14,291)</b>	<b>\$ (16,294)</b>	<b>\$ (39,291)</b>	<b>\$ (50,765)</b>	<b>\$ (41,936)</b>
Capx	(255)	(2,843)	(17,356)	(11,108)	(11,000)
Other	0	(60)	(16)	0	0
<b>Investing Activities</b>	<b>\$ (255)</b>	<b>\$ (2,903)</b>	<b>\$ (19,126)</b>	<b>\$ (11,108)</b>	<b>\$ (11,000)</b>
Equity	14,213	54,677	36,540	50,453	61,500
Debt	1,262	(1,862)	(603)	13,336	0
<b>Financing</b>	<b>\$ 15,475</b>	<b>\$ 52,815</b>	<b>\$ 35,937</b>	<b>\$ 63,788</b>	<b>\$ 61,500</b>
<b>Change in Cash</b>	<b>\$ (256)</b>	<b>\$ 33,619</b>	<b>\$ (22,480)</b>	<b>\$ 1,915</b>	<b>\$ 8,564</b>

Source: Arcimoto, Inc. and Dawson James Securities estimates



**Important Disclosures:**

**Price Chart:**



**Price target and ratings changes over the past three years:**

Initiated – Neutral – March 15, 2022 – Price Target NA  
 Update – Neutral – April 4, 2022 – Price Target NA  
 Update – Neutral – April 27, 2022 – Price Target NA  
 Update – Neutral – May 3, 2022 – Price Target NA  
 Update – Neutral – May 17, 2022 – Price Target NA  
 Update – Neutral – June 21, 2022 – Price Target NA  
 Update – Neutral – July 7, 2022 – Price Target NA  
 Update – Neutral – August 16, 2022 – Price Target NA  
 Rating Change – Sell – September 6, 2022 – Price Target \$0.45  
 Update – Sell – September 30, 2022 – Price Target \$0.45  
 Update – Sell – October 7, 2022 – Price Target \$0.45

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of September 8, 2022, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

**Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.**

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

#### **Ratings Definitions:**

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 20-Sep-22

	<b>Company Coverage</b>		<b>Investment Banking</b>	
<b>Ratings Distribution</b>	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	25	83%	3	12%
Market Perform (Neutral)	4	13%	1	25%
Market Underperform (Sell)	1	3%	0	0%
Total	30	100%	4	13%

#### **Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.